EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Decreased renal function predicts severe cytokine release syndrome after CAR ‐T‐cell therapy for large B‐cell lymphoma

Yasuyuki Arai iD, Tomoyasu Jo iD, Takayuki Sato, Masatoshi Sakurai, Daisuke Kaji iD, Toshio Kitawaki, Kazuyuki Shimada, Tatsu Shimoyama, Satoshi Yoshihara, Shinichi Makita, Nobuharu Fujii, Go Yamamoto und 10 weitere

British Journal of Haematology · 2026-06 · 208 (6) · 2124-2133

DOI: 10.1111/bjh.70488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 15.04.2026. Verfasst von Yasuyuki Arai und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Cytokine Release Syndrome, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL), and robust pre‐infusion predictors are needed for risk‐adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR‐T‐cell therapy between 2019 and 2024. Among 900 patients (median age 62 years), cumulative incidences of CRS within 30 days after infusion were 75.0% for any grade, 20.8% for grade ≥ 2 and 14.0% for grade ≥ 3. In multivariable analysis, lower estimated glomerular filtration rate (eGFR) (adjusted hazard ratio [aHR] 1.108 per 10 mL/min per 1.73 m 2 decrease; 95% confidence interval [CI] 1.015–1.209; p = 0.022), higher ferritin (aHR 1.006 per 100 ng/mL; 95% CI 1.001–1.010; p = 0.016), C‐reactive protein (CRP) (aHR 1.142 per mg/dL; 95% CI 1.091–1.195; p < 0.001) and lactate dehydrogenase (LDH) (aHR 1.073 per 100 U/L; 95% CI 1.008–1.142; p = 0.028) independently predicted grade ≥ 2 CRS. We then built a four‐factor CRS pre‐infusion risk evaluation model, cytokine release syndrome‐pre‐infusion risk evaluation (CRS‐PRE), that stratified grade ≥ 2 CRS risk into low, intermediate and high groups with incidences of 2.8%, 26.0% and 50.0% respectively. Decreased eGFR, a surrogate of host renal reserve, with elevated ferritin, CRP and LDH emerged as predictors of high‐grade CRS. The CRS‐PRE may facilitate risk‐adapted monitoring and intervention in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytokine Release SyndromeImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseHumansFemaleMiddle AgedMaleRetrospective StudiesAgedGlomerular Filtration RateAdult

Stichwörter der Autor:innen

chimeric antigen receptor T‐cell therapycytokine release syndromeestimated glomerular filtration ratelarge B‐cell lymphoma

Autor:innen und Institutionen

  • Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan.
  • Department of Cytotherapy, Kyoto University Hospital, Kyoto, Japan.
  • Department of Hematology and Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of Hematology, Toranomon Hospital, Tokyo, Japan.

ORCID-Profile: Yasuyuki Arai, Tomoyasu Jo, Daisuke Kaji, Yoshihiro Umezawa, Motohiro Kato

Förderung

  • Japan Society for the Promotion of Science
  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Arai, Y., Jo, T., Sato, T., Sakurai, M., Kaji, D., Kitawaki, T., Shimada, K., Shimoyama, T., Yoshihara, S., Makita, S., Fujii, N., Yamamoto, G., Kataoka, K., Sakaida, E., Goto, H., Nakashima, Y., Yoshida, A., Umezawa, Y., Kim, H., …, & Kato, K. (2026). Decreased renal function predicts severe cytokine release syndrome after CAR ‐T‐cell therapy for large B‐cell lymphoma. British Journal of Haematology, 208(6), 2124-2133. https://doi.org/10.1111/bjh.70488

Vancouver

Arai Y, Jo T, Sato T, Sakurai M, Kaji D, Kitawaki T, et al. Decreased renal function predicts severe cytokine release syndrome after CAR ‐T‐cell therapy for large B‐cell lymphoma. British Journal of Haematology. 2026;208(6):2124-2133. doi:10.1111/bjh.70488

BibTeX
@article{Arai2026,
  author = {Arai, Yasuyuki and Jo, Tomoyasu and Sato, Takayuki and Sakurai, Masatoshi and Kaji, Daisuke and Kitawaki, Toshio and Shimada, Kazuyuki and Shimoyama, Tatsu and Yoshihara, Satoshi and Makita, Shinichi and Fujii, Nobuharu and Yamamoto, Go and Kataoka, Keisuke and Sakaida, Emiko and Goto, Hideki and Nakashima, Yasuhiro and Yoshida, Akiyo and Umezawa, Yoshihiro and Kim, Haryoon and Kato, Motohiro and Atsuta, Yoshiko and Kato, Koji},
  title = {Decreased renal function predicts severe cytokine release syndrome after CAR ‐T‐cell therapy for large B‐cell lymphoma},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {6},
  pages = {2124--2133},
  doi = {10.1111/bjh.70488}
}
Kostenlos starten →